Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo‐controlled trial (<scp>CAPTIVATE</scp>)Lin Chang, Jan Tack, Kye Gilder et al.|Neurogastroenterology & Motility|2023Cited by 33